ClinicalTrials.Veeva

Menu

Platelet Rich Fibrin+1% Alendronate in Treatment of Chronic Periodontitis

G

Government Dental College and Research Institute, Bangalore

Status and phase

Completed
Phase 3
Phase 2

Conditions

Chronic Periodontitis

Treatments

Procedure: Open flap debridement (OFD)
Procedure: OFD with Platelet rich fibrin (PRF)+1% Alendronate
Procedure: OFD with Platelet rich fibrin (PRF)

Study type

Interventional

Funder types

Other

Identifiers

NCT02518152
GDCRI/ACM/PG/PhD/2/2013-2014N

Details and patient eligibility

About

The present study is designed to evaluate the combined efficacy of Platelet Rich Fibrin (PRF) and 1% Alendronate (ALN) with open flap debridement (OFD) in treatment of intrabony defects in chronic periodontitis patients.

Full description

Background: Platelet-rich fibrin (PRF) is a second-generation platelet concentrate, act as reservoirs of growth factors and cytokines which are the key factors for regeneration of the bone and maturation of the soft tissue. Alendronate (ALN), a potent member of bisphosphonate group is known to promote tissue regeneration by inhibiting osteoclastic bone resorption and promoting osteoblastogenesis. The present study was designed to evaluate the combined efficacy of PRF and 1% ALN with open flap debridement (OFD) in treatment of intrabony defects in chronic periodontitis patients.

Methods: Ninety patients with single defects were categorized into three groups: OFD alone, OFD with PRF,OFD with PRF+1% ALN. Clinical parameters; site specific plaque index (PI), modified sulcus bleeding index (mSBI), probing depth (PD), clinical attachment level (CAL) and gingival marginal level (GML) were recorded at baseline before surgery and 9 months post-operatively. Percentage radiographic intra-bony defect depth reduction (IBD) was evaluated at baseline and 9 months.

Enrollment

90 patients

Sex

All

Ages

30 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria

  • Presence of 3-wall IBD ≥3 mm deep (distance between alveolar crest and base of the defect on an Intra-oral Periapical Radiograph [IOPA]) along with an interproximal probing depth (PD) ≥5 mm after phase I therapy (scaling and root planing[SRP]) in asymptomatic teeth.

Exclusion Criteria:

  • Aggressive Periodontitis patients;
  • Systemic conditions known to affect the periodontal status;
  • medications known to affect the outcomes of periodontal therapy;
  • Hematological disorders and insufficient platelet count (<200,000/mm3);
  • Pregnancy/lactation;
  • Smoking and tobacco use in any form
  • Immunocompromised individuals.
  • Those having unacceptable oral hygiene (plaque index27 [PI] >1.5) after reevaluation of Phase I therapy .
  • Teeth with furcation involvement, non-vital teeth, carious teeth indicated for restorations and mobility of at least grade II were also excluded.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

90 participants in 3 patient groups

Group 1
Active Comparator group
Description:
Scaling and Root Planing (SRP) with Open flap debridement (OFD) alone for treating periodontal defect
Treatment:
Procedure: Open flap debridement (OFD)
Group 2
Active Comparator group
Description:
SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF) for treating periodontal defect
Treatment:
Procedure: OFD with Platelet rich fibrin (PRF)
Group 3
Active Comparator group
Description:
SRP with Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate for treating periodontal defect
Treatment:
Procedure: OFD with Platelet rich fibrin (PRF)+1% Alendronate

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems